Abstract
A simple and sensitive thin-layer chromatographic method has been established for analysis of rasagiline mesylate in pharmaceutical dosage form. Chromatography on silica gel 60 F254 plates with 6 : 1 : 2(v/v/v) butanol-methanol water as mobile phase furnished compact spots at Rf 0.76±0.01. Densitometric analysis was performed at 254 nm. To show the specificity of the method, rasagiline mesylate was subjected to acid, base, neutral hydrolysis, oxidation, photolysis, and thermal decomposition, and the peaks of degradation products were well resolved from that of the pure drug. Linear regression analysis revealed a good linear relationship between peak area and amount of rasagiline mesylate in the range of 100–350 ng/band. The minimum amount of rasagiline mesylate that could be authentically detected and quantified was 11.12 and 37.21 ng/band, respectively. The method was validated, in accordance with ICH guidelines for precision, accuracy, and robustness. Since the method could effectively separate the drug from its degradation products, it can be regarded as stability indicating.
Highlights
Rasagiline mesylate (Figure 1) is a chemical inhibitor of the enzyme monoamine oxidase type-B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system
There are many methods reported in the literature for analysis of rasagiline mesylate, for example, GC-MS [2], HPLC methods [3,4,5], LC-MS/MS in human plasma [6], and spectrophotometric methods [7, 8]
Several solvent mixtures in different ratios were tested to obtain a compact band of rasagiline mesylate
Summary
Rasagiline mesylate (Figure 1) is a chemical inhibitor of the enzyme monoamine oxidase type-B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. Rasagiline is a propargylamine-based drug indicated for the treatment of idiopathic Parkinson’s disease. Rasagiline is freely soluble in water and ethanol and sparingly soluble in isopropyl alcohol. It is a chiral compound with one asymmetric carbon atom in a five-member ring with an absolute R-configuration which is produced as single enantiomer [1]. No available densitometric method for the simultaneous separation of rasagiline mesylate from degradation products has been reported. The objective of the present study is to develop and validate a new HPTLC method for the estimation of rasagiline mesylate in bulk drug and its dosage form
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
